In conclusion, our data on using phenotypic profiles of MTB-specific CD4 T cells as a surrogate marker for treatment efficiency warrant further research and methodological simplification to define its usefulness in standard clinical sttings and during TB drug trials. Here, CD4 is linked to tuberculosis.